Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 8:00 PM JST
Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/12 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.11020475Cold-adapted live attenuated severe acute respiratory syndrome coronavirus and vaccine containing the same
US 01.06.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No 17080224 Applicant The Industry & Academic Cooperation in Chungnam National University (IAC) Inventor Sang-Heui Seo

Disclosed is cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) prepared by infecting cells with severe acute respiratory syndrome coronavirus and then adapting the severe acute respiratory syndrome coronavirus to a temperature from 37° C. to 22° C. in a step by step manner. Further, a vaccine containing the cold-adapted live attenuated severe acute respiratory syndrome coronavirus (SARS-CoV-2) is disclosed.

2.WO/2021/156490CORONA VIRUS BINDERS
WO 12.08.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/EP2021/052885 Applicant VIB VZW Inventor SCHEPENS, Bert
The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses. More specifically the invention relates to compositions comprising single domain antibodies, or specifically VHHs, and compositions comprising multivalent binding agents comprising IgG Fc fusions thereof, specifically VHH-Fc fusions thereof, even more specifically comprising heavy chain only VHH72-S56A-IgG1-Fc fusions, or compositions comprising any humanized form of any one thereof, and are capable of specifically binding and neutralizing SARS-Corona viruses, specifically SARS-Cov-2 virus. The compositions are useful in the diagnosis of Sarbecoviruses, and specifically SARS-CoV-2 virus, and in prophylactic and/or therapeutic treatment of a condition resulting from infections with Sarbecoviruses, specifically SARS-Corona or SARS-CoV-2 virus, or mutants thereof.
3.WO/2021/195136DEVICES FOR DETECTING ANTIBODIES TO CORONAVIRUS ANTIGENS
WO 30.09.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2021/023762 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor FELGNER, Phillip L.
In alternative embodiments, provided are multiplexed systems, compositions, including products of manufacture such as arrays, microarrays and biochips, and kits, and methods, for detecting presence of a coronavirus in a sample, or to detect a coronavirus, e.g., COVID-19, infection. In alternative embodiments, provided are methods for detecting the presence of a coronavirus infection in an individual. In alternative embodiments, provided are vaccines and methods for using them to prevent, mitigate or lessen to effects of, or treat a coronavirus infection in an individual.
4.WO/2021/254473IMMUNOGENIC COMPOSITION AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)
WO 23.12.2021
Int.Class C12N 15/50
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
50Coronaviridae, e.g. infectious bronchitis virus, transmissible gastroenteritis virus
Appl.No PCT/CN2021/100826 Applicant MEDIGEN VACCINE BIOLOGICS CORPORATION Inventor KUO, Tsun-Yung
Provided an immunogenic composition against severe acute respiratory syndrome coronavirus (SARS-CoV-2), especially to an immunogenic composition having a recombinant SARS-CoV-2 S protein and adjuvant.
5.20210315988VACCINATION AGAINST CORONAVIRUS WITH POLIOMYELITIS VACCINE
US 14.10.2021
Int.Class A61K 39/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
125Picornaviridae, e.g. calicivirus
13Poliovirus
Appl.No 17155953 Applicant E-MO Biology Inc. Inventor Qiyi Xie

Provided herein is a method for preventing a person from an infection by a Coronaviridae virus with a poliomyelitis vaccine. Also provided herein is a method of inducing a protective immune response against a Coronaviridae virus with a poliomyelitis vaccine.

6.WO/2021/229591NOVEL USE OF NON-IONIC SURFACTANT FOR THE TREATMENT OF COVID–19
WO 18.11.2021
Int.Class A61K 9/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
Appl.No PCT/IN2020/050643 Applicant KRISHNAMACHARI, Ramu Inventor RITHVIK, K
The present invention relates to a novel use of non-ionic surfactants for the treatment of diseases caused by viruses. The present invention particularly relates to the use of non-ionic surfactants for the treatment of a disease known as COVID 19 caused by coronavirus SARS-CoV-2. The present invention further teaches the use of taste masking agents/excipients. The present invention is further believed to be related to cleansing the coronaviruses from buccal cavities, throat or within the body of a subject by not allowing the said virus to attach to any cells of mucosal layers or epithelial cells thus allowing them to pass out of the body or getting digested inside the body. For this reason the molecules or the composition used herein of the present invention is termed by the applicant as "INTERNAL SOAP".
7.WO/2021/163456T CELL EPITOPES AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION, DIAGNOSIS, AND TREATMENT OF COVID-19
WO 19.08.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/017825 Applicant EPIVAX, INC. Inventor DE GROOT, Anne
The present disclosure generally relates to novel epitope-based compositions, including vaccines, against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and diseases caused by SARS-CoV-2, including the highly contagious coronavirus disease 2019 (which has been termed and may be referred to herein as "COVID-19", "2019-nCoV", or the "2019 novel coronavirus". The disclosure relates to immunogenic polypeptides and the uses thereof, particularly in vaccine compositions. The disclosure also relates to nucleic acids, vectors, and cells which express the polypeptides and the uses thereof. The polypeptides more specifically comprise an agretope predicted to be a ligand of HLA class I and/or HLA class II MHC molecules, as well as an epitope that is predicted to be recognized by T-cells in the context of MHC class I and/or class II molecules. The compositions are particularly suited to produce vaccines, particularly for vaccinating against SARS-CoV-2 infection and related diseases caused by SARS-CoV-2, including COVID-19.
8.WO/2021/163398T CELL EPITOPE CLUSTERS AND RELATED COMPOSITIONS USEFUL IN THE PREVENTION, DIAGNOSIS, AND TREATMENT OF COVID-19
WO 19.08.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/017748 Applicant EPIVAX, INC. Inventor DE GROOT, Anne
The present disclosure relates to novel epitope-based compositions, including vaccines, against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and diseases caused by SARS-CoV-2, including the highly contagious coronavirus disease 2019. The disclosure relates to immunogenic polypeptides (including concatemeric polypeptides, hybrid Ii-key constructs, and chimeric or fusion polypeptides as disclosed herein) and the uses thereof, particularly in vaccine compositions. The disclosure also relates to nucleic acids, vectors, and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an agretope predicted to be a ligand of HLA class I and/or HLA class II MHC molecules, as well as an epitope that is predicted to be recognized by T-cells in the context of MHC class I and/or class II molecules. The compositions are particularly suited to produce vaccines, particularly for vaccinating against SARS-CoV-2 infection and related diseases caused by SARS-CoV-2, including COVID-19.
9.WO/2021/236415SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19
WO 25.11.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/US2021/032203 Applicant THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Inventor HORWITZ, Marcus, A.
Embodiments of the invention include immunogenic compositions that comprise an attenuated recombinant Francisella tularensis subspecies holarctica Live Vaccine Strain (LVS) having a deletion in a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens present on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Embodiments of the invention also include methods of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant Live Vaccine Strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens expressed by a severe acute respiratory syndrome coronavirus 2 (SAR8- CoV-2) polypeptide.
10.WO/2021/207303IMMUNE STIMULATION AGAINST CORONAVIRUS INFECTIONS
WO 14.10.2021
Int.Class A61K 31/739
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
739Lipopolysaccharides
Appl.No PCT/US2021/026103 Applicant ALSATECH, INC. Inventor NICOLAU, Claude
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of infections that are caused by or associated with coronaviruses (e.g., SARS-CoV-2). In particular, the present invention provides novel methods and compositions for eliciting a highly specific and highly effective immune response in a patient, which is capable of preventing or alleviating coronavirus infections, or symptoms associated with coronavirus infections, including the novel SARS-CoV-2 infection, COVID-19.